Marco Meglio

Vibrance-2 is a double-blind, placebo-controlled trial with 80 participants, assessing three doses of ALKS 2680 over eight weeks

A recent prospective study reveals significant alterations in heavy metal and trace element levels among patients with migraine, suggesting these imbalances may play a role in the pathogenesis and progression of the condition.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on epilepsy surgery.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sharon Cohen, MD. [LISTEN TIME: 20 minutes]

The data suggest that PrimeC's modulation of iron homeostasis may be a key mechanism in its therapeutic effect, supporting its advancement to phase 3 trials.

The medical director of the Toronto Memory Program at the University of Toronto gave clinical perspective on the promise of mivelsiran, an investigational RNA interference therapeutic, and the idea behind using RNA therapies to treat Alzheimer disease. [WATCH TIME: 5 minutes]

The chief medical officer and head of Research & Development at Cognition Therapeutics discussed data from the phase 2 proof-of-concept SHINE study assessing CT1812, a small molecule oligomer antagonist, in early-stage Alzheimer disease.

The study highlights a dramatic decrease in income for patients following disease onset and a significantly higher proportion of them requiring social welfare jobs or disability pensions.

The chairman and chief executive officer at Biomed provided insight on the hypothesis behind a new phase 3 study assessing NA-831, an agent with neurogenesis effects, with lecanemab, a previously approved drug for Alzheimer disease. [WATCH TIME: 7 minutes]

Most relapses occurred before patients resumed immunotherapy after giving birth, suggesting that continued immunosuppression during pregnancy might help prevent attacks.

The professor of neurology and Diana Davis Spencer Foundation Chair at the Jackson Laboratory discussed the emerging importance of microglia in the context of Alzheimer disease research and its potential implications for clinical trials. [WATCH TIME: 4 minutes]

The double-blind, single-dose, 5-period crossover study is expected to include approximately 40 patients with narcolepsy type 1 to test 3 dose strengths of E2086.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on care of frontotemporal dementia.

The study found a 98% agreement between treating physicians’ initial diagnoses and the new MOGAD criteria.

The study suggests that overall, migraine is not directly related to traditional CVRFs, and further research is needed, especially in younger populations, to explore these relationships over longer periods.

Peter Vanderklish, PhD, chief science officer at Spingogenix, commented on a recently initiated phase 2 trial assessing investigational SPG302, a synaptic-regenerative agent in development for Alzheimer disease.

AOC 1044, an investigational antisense oligonucleotide treatment for patients with Duchenne muscular dystrophy, has previously been granted orphan drug and fast track designation by the FDA.

Medtronic's asleep DBS approval could expand treatment options for patients unable to tolerate awake surgery, enhancing access to deep brain stimulation therapy.

The drug showed a highly favorable pharmacokinetic profile, with maximal concentrations (Tmax) achieved within 1.5 to 2 hours and a mean terminal elimination half-life ranging between 8 to 12 hours.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on care of idiopathic hypersomnia.

Early use of Ceribell’s POC-EEG system significantly improves detection of nonconvulsive seizures, reduces ICU length of stay, and enhances patient outcomes compared to conventional EEG.

Results showed that the DAAE Score performs well, with consistent risk estimates across the derivation (JMSC), internal-validation (JMSC), and external-validation (MSCA) dataset across treatment centers internationally.

A recent trial showed that post-stroke patients using a socially assistive robot (SAR) for upper-extremity rehab achieved significant motor function improvements, with 100% meeting or exceeding minimal clinical improvements.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Phil Jochelson, MD. [LISTEN TIME: 20 minutes]

Scholar Rock's TOPAZ phase 2 trial shows sustained motor function improvements in SMA patients treated with apitegromab over 48 months, with phase 3 results expected soon.

Anavex Life Sciences intends to submit a full regulatory application for blarcamesine as a potential treatment for AD in Europe by Q4 2024.

Marketed as Crexont, the combination extended- and immediate-release treatment is indicated for treatment of PD, and is anticipated to be available in the United States in September 2024.

The positive data from this Phase 1a trial will inform the dosing for the upcoming Phase 1b portion in patients with AD, expected to commence in the second half of 2024.

The personalized medicine lead at Linus Health provided clarity on a new outcome measure that captures various perspectives about what matters to individuals and their brain health.

In pediatric patients, the average treatment intensity was 22.8% of the maximum stimulator intensity, with slightly lower intensity levels compared to previous studies in adolescents and adults.